AHCO stock forecast, quote, news & analysis
AdaptHealth Corp is engaged in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services... Show more
AdaptHealth (AHCO) Stock Analysis: Portfolio Simplification and Cost Discipline Drive a Turnaround
Key Takeaways
- AdaptHealth shares held to a modest single-digit move over the trailing 30 days, shifting from roughly $5.71 in mid-September to about $6.11 in recent sessions.
- The company is a national leader in home medical equipment and healthcare-at-home solutions, anchored by its Sleep Health and Respiratory Health segments.
- Portfolio simplification is a central theme, including an agreement to sell the Diabetes Health business for $235 million and the exit of custom rehab assets.
- A large West Coast capitated contract drove record volume but pressured near-term profitability, contributing to a reset of full-year 2026 adjusted EBITDA guidance.
- Balance-sheet actions, a new CFO, and a focus on de-leveraging underscore management's emphasis on execution over expansion.
Current Market Snapshot
AdaptHealth Corp. trades on the Nasdaq with a market capitalization of roughly $784 million. The stock has been consolidating in the low single digits, and its 52-week range of approximately $5.21 to $13.43 reflects a multi-quarter decline from prior highs. With a beta near 1.42, the shares tend to be more volatile than the broader market, making sentiment and single-stock catalysts especially relevant to near-term price action.
Wall Street's view remains constructive on a consensus basis. Sell-side coverage carries a consensus "Strong Buy" rating with an average 12-month price target around $8.86, well above recent trading levels. Baird separately lowered its target to $9 from $10 while maintaining an Outperform rating following a recent conference update. The gap between analyst targets and the current price illustrates how investor debate centers on execution risks tied to large capitated contracts and ongoing cost pressures.
AdaptHealth (AHCO) Business Overview and Competitive Position
AdaptHealth is one of the largest providers of patient-centered, healthcare-at-home solutions in the United States. The company distributes home medical equipment (HME), medical supplies, and related services, with reportable segments spanning Sleep Health, Respiratory Health, and Wellness at Home. Its product and service mix includes CPAP and BiLevel sleep therapy, oxygen and ventilation equipment, enteral nutrition, and a range of supplies delivered directly to patients' homes.
The company's scale is a defining competitive advantage. AdaptHealth serves millions of patients through a national footprint and has established large capitated agreements with major health plans, including a multi-state relationship with Humana and a substantial West Coast arrangement. Its digital platform, myApp, has grown to more than 500,000 registered users, supporting a technology-enabled approach to scheduling, resupply, and patient engagement. Investors follow the stock closely because AdaptHealth sits at the intersection of durable healthcare demand, an aging population, and the broader shift of care into the home.
Recent Developments Driving AHCO
AdaptHealth's second-quarter 2026 results, reported in early August, framed the stock's recent narrative. Continuing-operations net revenue rose 12.7% year over year to $740.3 million, with 15.9% organic growth driven by strong performance in Sleep Health and Respiratory Health. However, adjusted EBITDA declined to $132 million from $136.4 million a year earlier, and the company recorded a $144.2 million goodwill impairment while lowering its full-year profitability outlook.
The primary pressure point has been a large West Coast capitated contract that delivered higher-than-expected volumes but also elevated labor and logistics costs. Management cited a $15 million shortfall in the second quarter and an additional projected impact in the second half, alongside a supplier price increase. The company has outlined remediation steps, including workflow standardization, expanded drop-shipping, and technology deployment, while maintaining a target of roughly 20% long-term margins for its capitated business.
Portfolio actions have also been prominent. In July, AdaptHealth announced an agreement to sell its Diabetes Health business for $235 million, moving that segment to discontinued operations and refocusing the portfolio on sleep, respiratory, and related home medical equipment. The company also discontinued certain low-margin Wellness at Home products and completed the disposition of its remaining custom rehab assets. In May, it expanded its relationship with Humana OneHome, transitioning 478,000 members in South Florida and Texas, and brought its Humana capitated footprint to 33 states plus the District of Columbia.
Leadership and capital structure changes added to the story. AdaptHealth named Harriss T. Currie as Chief Financial Officer effective September 9, 2026, succeeding Jason Clemens. Earlier in the year, the company completed a $1.1 billion refinancing of its senior secured credit facility, extending maturities, lowering its weighted average cost of debt, and providing committed capital to redeem its 2028 senior notes.
Trending AI Robots
For investors who prefer a data-driven approach to monitoring stocks like AdaptHealth, Tickeron's Trending AI Robots page offers a curated view of automated trading strategies. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of tickers, but only the top-performing and most relevant bots are surfaced in this section. Each bot operates with its own strategy, timeframe, and performance metrics, allowing users to compare approaches rather than relying on a single signal. The page is designed to help traders identify patterns and strategies that have demonstrated recent traction. Explore the Trending AI Robots section to see which automated strategies are currently drawing attention.
2026 Outlook and What Investors Should Watch
AdaptHealth has reset its full-year 2026 guidance on a continuing-operations basis, targeting net revenue of $2.85 billion to $2.89 billion, adjusted EBITDA of $490 million to $520 million, and free cash flow of $80 million to $120 million. The key variable for investors is whether the company can convert strong organic volume growth into margin improvement, particularly as the West Coast capitated contract moves toward run-rate profitability.
Several factors will shape the outlook. The completion of the Diabetes Health divestiture and the removal of stranded corporate overhead will be closely watched, as will progress toward the company's stated 2.5x net leverage target from its current level near 3.0x. On the operational side, the potential lifting of a government-imposed DME moratorium that has blocked new Medicare billing numbers for AdaptHealth's newest locations represents an upside catalyst. Counterbalancing risks include supplier cost inflation, reimbursement changes, competitive bidding dynamics, and the execution burden of integrating large capitated patient populations. With quarterly results and management commentary on cost discipline serving as the primary near-term catalysts, investors will likely remain focused on margin trajectory rather than top-line growth alone.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
AHCO's RSI Oscillator peaks and leaves overbought zone
The 10-day RSI Oscillator for AHCO moved out of overbought territory on October 16, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 instances where the indicator moved out of the overbought zone. In 22 of the 27 cases the stock moved lower in the days that followed. This puts the odds of a move down at 81%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 42 of 57 cases where AHCO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 74%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AHCO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
AHCO broke above its upper Bollinger Band on October 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for AHCO entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 06, 2026. You may want to consider a long position or call options on AHCO as a result. In 80 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
AHCO moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for AHCO crossed bullishly above the 50-day moving average on October 13, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 76%.
Following a +4.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where AHCO advanced for three days, in 225 of 301 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.590) is normal, around the industry mean (2.923). P/E Ratio (-3.653) is within average values for comparable stocks, (2.388). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.240) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. AHCO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AHCO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of medical products for both rental and sale
Industry MedicalNursingServices